RE:RE:33.3% CR rate, with 50.0% data pending
floatinketucky wrote: In support of the tertiary objective, all patients have experienced some transient grade 1 or grade 2 AEs (e.g.: bladder spasms, constipation, urge incontinence, fatigue, urinary frequency, hematuria, penile discomfort, urinary urgency, pain, urinary tract infections and other) where > 80% have completely resolved with 180 days.
Very good!!!!!
Good point floatinketucky! We can't forget about SAFETY. Safety plays a major role in an FDA approval, & TLT can boast one of the safest so far...& leading the pack in fewest treatments. Our high efficacy so far in optimized patients (80% CR in evaluable patients, including the two from Ph 1) certainly adds significant promise to our chances for approval. And as I noted before, any first treatment non-responder still has a chance to become CR after the second treatment. Our "true" efficacy/durable response (patients having received two optimized treatments) will become much more evident at the 210 day assessment, or 90 days after the 2nd treatment. JMHO.